New RSV vaccine shows promise for older adults in india
NCT ID NCT06614725
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 study tested a single dose of an investigational RSV vaccine in 751 adults aged 60 and older, and those 50-59 at increased risk for severe RSV. The goal was to see how well the vaccine boosts the immune system and whether it is safe. Participants received either the vaccine or a placebo, and researchers measured antibody levels and tracked any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RSVPreF3 OA investigational vaccine
What this could lead to
If successful, this vaccine could help protect older adults and those at higher risk from severe RSV-related lung infections.
What could go wrong
This trial is completed but results are not yet published. The vaccine may not work as well in real-world settings or may cause side effects like pain or swelling at the injection site.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Kanpur, Uttar Pradesh, 208002, India
-
GSK Investigational Site
Ahmedabad, 380015, India
-
GSK Investigational Site
Ahmedabad, 380061, India
-
GSK Investigational Site
Aligarh, 202002, India
-
GSK Investigational Site
Bangalore, 560002, India
-
GSK Investigational Site
Belagavi, 590019, India
-
GSK Investigational Site
Darjeeling, 734012, India
-
GSK Investigational Site
Delhi, 110060, India
-
GSK Investigational Site
Kelambākkam, 603103, India
-
GSK Investigational Site
Kochi, 682026, India
-
GSK Investigational Site
Kolkata, 700073, India
-
GSK Investigational Site
Pune-411 043, 411043, India
-
GSK Investigational Site
Raipur, India
-
GSK Investigational Site
Vadu Budruk Pune, 412216, India